The global genomic clinical decision support market was valued at USD 1.24 billion in 2025. The market is estimated at USD 1.42 billion in 2026 and is projected to reach USD 5.18 billion by 2036, at a CAGR of 13.8% during the forecast period 2026-2036. This report examines oncology profiling, pharmacogenomic prescribing, EHR integration, CDS technologies, guidelines, case studies, regulation and reimbursement, business models, competition, and growth opportunities.
The market covers the software, knowledge bases and content, and services that turn genomic test results into recommendations clinicians can use at the point of care. It includes oncology tools that link tumor alterations to approved therapies, guidelines, and trials; pharmacogenomic alerts and dosing advice inside prescribing systems; support for hereditary cancer, cardiovascular, rare, and inherited conditions, including risk management and cascade testing of relatives; reproductive and prenatal decision support; EHR genomic modules that hold discrete results and fire alerts; curated variant, biomarker, therapy, and guideline databases; and implementation, integration, and curation services. Revenue from the genomic tests themselves, secondary analysis and data storage, general CDS without genomic content, imaging AI, and consumer genetic reports are excluded.
Most clinicians who order or act on genomic results are not genetics specialists, and test volumes are outpacing growth in the genetics workforce. In England, the NHS PROGRESS pharmacogenomics trial, now running in 20 general practices with the PROGRESSRx tool feeding results into prescribing systems, reported that 93% of participants had a clinically relevant variant in one or more of the four genes studied, that about 80% of the guidance shown was followed, and that 35% of participants had their prescription changed. The U.S. Food and Drug Administration (FDA) issued revised CDS software guidance in January 2026 that replaces its 2022 version and explains which functions are exempt from device rules under the 21st Century Cures Act.
Insurance coverage for pharmacogenomic panels differs from one payer and country to the next, preemptive testing is often not covered, and decision support itself is rarely paid for directly, so health systems must justify spending through safety, efficiency, and outcome gains. Clinicians already face many EHR alerts, and genomic prompts that are too frequent, not actionable, or poorly timed tend to be ignored or switched off. Keeping knowledge bases current requires costly expert curation, and different databases and laboratories may classify the same variant differently. Many results still arrive as PDFs rather than discrete data, which limits automation.
Preemptive pharmacogenomics at population scale is a significant opportunity, since a single panel test can guide prescribing for many drugs over a lifetime, and national and large integrated health systems are now evaluating such programs. AI and large language models can speed literature review, evidence extraction, clinician summaries, and trial matching, and the FDA's 2026 guidance clarifies which clinician-facing functions may fall outside device regulation. Trial matching links patients to biomarker-driven studies and generates real-world data of value to drug developers, while genomic risk tools for hereditary cancer and familial hypercholesterolemia and rapid genome sequencing for critically ill infants extend demand beyond oncology. Key trends include the move from static reports to decision support inside EHRs and prescribing systems, the combination of testing, data, and CDS in single platforms, and the reuse of genomic results across a patient's lifetime.
By component, the genomic clinical decision support market is segmented into software, knowledge bases & content, and services. Software, including standalone CDS platforms and EHR-embedded genomic modules, is expected to hold the largest share in 2026, as laboratories, cancer centers, and health systems have adopted oncology decision support, pharmacogenomic CDS, and interpretation and reporting tools, and EHR vendors are building genomic modules into their systems. Services are set to grow at the highest CAGR, driven by the difficulty of linking genomic results with EHRs and laboratory systems, demand for expert curation and interpretation, and the need to design, roll out, and tune genomic alerts and workflows. Knowledge bases and content are also expected to grow strongly as biomarkers, therapies, and guidelines multiply.
By application, the genomic clinical decision support market is segmented into oncology, pharmacogenomics, rare & inherited diseases, hereditary cancer & cardiovascular risk, reproductive & prenatal health, and other applications. Oncology, which covers therapy selection, clinical trial matching, and disease monitoring, is expected to lead in 2026, reflecting high volumes of comprehensive profiling and liquid biopsy tests, the growing number of biomarker-linked therapies and trials, and the difficulty oncologists face in reading complex reports. Pharmacogenomics is projected to record the highest CAGR, supported by the move toward preemptive testing, the delivery of results inside prescribing systems, evidence from the NHS PROGRESS trial that guidance changes prescribing for many patients, and well-established CPIC and DPWG guidelines. Hereditary risk tools are gaining use as testing reaches primary care and cardiology.
By integration type, the genomic clinical decision support market is segmented into EHR-integrated and standalone solutions, with standalone including web-based tools and laboratory portals. Standalone solutions are expected to account for the largest share in 2026, as web-based oncology platforms, laboratory reporting portals, and clinician applications from testing companies are widely used and need little EHR integration. EHR-integrated solutions are set to grow at the highest CAGR, driven by the uptake of EHR genomic modules, the need for drug-gene alerts at the moment of prescribing, wider exchange of structured results through HL7 FHIR Genomics, and clinicians' preference for guidance inside the systems they already use. This favors CDS providers with close EHR vendor ties.
By deployment mode, the genomic clinical decision support market is segmented into cloud-based and on-premise deployment. Cloud-based deployment is expected to hold the largest share in 2026 and to grow at the higher CAGR, as oncology tools and knowledge bases are delivered as cloud services that can be updated continuously, more health systems run cloud-hosted EHRs, and cloud solutions cost less to implement for smaller health systems and practices.
By end user, the genomic clinical decision support market is segmented into hospitals & health systems, clinical & reference laboratories, ambulatory & primary care practices, specialty clinics & cancer centers, and other end users such as pharmacies and payers. Hospitals & health systems are expected to account for the largest share in 2026, since genomic testing, cancer care, and EHR spending are concentrated in hospitals and integrated systems, they run genomic modules and pharmacogenomic programs, and they need enterprise-wide decision support. Ambulatory & primary care practices are expected to grow at the highest CAGR, supported by pharmacogenomic testing in general practice, as shown by the NHS PROGRESS trial, wider use of hereditary risk information in primary care, and adoption of cloud-based CDS by outpatient practices.
North America is expected to be the largest regional genomic clinical decision support market in 2026, supported by high oncology testing volumes, health system adoption of EHRs with genomic modules, pharmacogenomic programs at academic medical centers and integrated systems, and the U.S. base of Epic Systems, Oracle Health, Illumina, Tempus AI, and Velsera. Europe holds a significant share, backed by the NHS Genomic Medicine Service in England, the NHS PROGRESS trial, the inclusion of pharmacogenetic guidelines in the national medicines database of the Netherlands, and the presence of QIAGEN, Roche, and SOPHiA GENETICS, while software providing diagnostic or therapeutic information may fall under the EU IVDR or MDR.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, as oncology genomic testing grows in China, Japan, South Korea, and Australia, Japan covers cancer genomic medicine under its national health insurance system, Singapore runs population genomics programs, hospitals adopt EHRs, and interest in pharmacogenomics rises because several drug-response variants are more common in Asian populations. In the Middle East & Africa, Gulf genome projects in Saudi Arabia, the UAE, and Qatar support demand, while oncology genomic testing in Brazil and Mexico drives growth in Latin America.
The genomic clinical decision support market is moderately fragmented, with EHR vendors, CDS and interpretation software firms, testing companies, and content providers active across applications and regions. Vendors compete on the depth and currency of curated knowledge, EHR and laboratory system integration, trial matching, regulatory compliance, ease of use, and evidence of clinical utility. Leading players are embedding genomic results in EHR workflows, expanding curated content, applying AI to curation and interpretation, building trial matching tools, and combining testing, decision support, and data services. Recent developments include the FDA's January 2026 CDS software guidance, strong 2026 growth in Tempus AI's testing and data businesses, and Tempus AI's pending acquisition of Personalis.
Key companies profiled in the report include Epic Systems Corporation (U.S.), Oracle Corporation (Oracle Health) (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Illumina, Inc. (U.S.), Tempus AI, Inc. (U.S.), SOPHiA GENETICS SA (Switzerland), and Velsera, Inc. (U.S.).
The market covers the software, knowledge bases and content, and services that turn genomic test results into recommendations clinicians can use at the point of care. It includes oncology tools that link tumor alterations to approved therapies, guidelines, and trials; pharmacogenomic alerts and dosing advice inside prescribing systems; support for hereditary cancer, cardiovascular, rare, and inherited conditions, including risk management and cascade testing of relatives; reproductive and prenatal decision support; EHR genomic modules that hold discrete results and fire alerts; curated variant, biomarker, therapy, and guideline databases; and implementation, integration, and curation services. Revenue from the genomic tests themselves, secondary analysis and data storage, general CDS without genomic content, imaging AI, and consumer genetic reports are excluded.
Most clinicians who order or act on genomic results are not genetics specialists, and test volumes are outpacing growth in the genetics workforce. In England, the NHS PROGRESS pharmacogenomics trial, now running in 20 general practices with the PROGRESSRx tool feeding results into prescribing systems, reported that 93% of participants had a clinically relevant variant in one or more of the four genes studied, that about 80% of the guidance shown was followed, and that 35% of participants had their prescription changed. The U.S. Food and Drug Administration (FDA) issued revised CDS software guidance in January 2026 that replaces its 2022 version and explains which functions are exempt from device rules under the 21st Century Cures Act.
Market Dynamics
Comprehensive genomic profiling in oncology is a major driver of the genomic clinical decision support market, as guidelines recommend tumor profiling for many advanced cancers, the list of biomarker-driven targeted therapies and immunotherapies keeps growing, and liquid biopsy and molecular residual disease testing are spreading, leaving oncologists with complex reports to interpret and trials to find. Pharmacogenomic results matter only if they appear whenever a relevant drug such as an antidepressant, statin, anticoagulant, antiplatelet agent, or proton pump inhibitor is prescribed, often years after testing, so health systems running preemptive programs need CDS that stores results and triggers alerts, guided by CPIC and DPWG recommendations. Whole-exome and whole-genome sequencing and large panels produce many variants of uncertain significance, and the evidence behind each changes as research and guidelines evolve. EHR genomic modules that store discrete genotypes and variants, such as Epic Systems' Genomics module, and HL7 FHIR Genomics standards for structured results are making automated alerts and population-level patient finding possible.Insurance coverage for pharmacogenomic panels differs from one payer and country to the next, preemptive testing is often not covered, and decision support itself is rarely paid for directly, so health systems must justify spending through safety, efficiency, and outcome gains. Clinicians already face many EHR alerts, and genomic prompts that are too frequent, not actionable, or poorly timed tend to be ignored or switched off. Keeping knowledge bases current requires costly expert curation, and different databases and laboratories may classify the same variant differently. Many results still arrive as PDFs rather than discrete data, which limits automation.
Preemptive pharmacogenomics at population scale is a significant opportunity, since a single panel test can guide prescribing for many drugs over a lifetime, and national and large integrated health systems are now evaluating such programs. AI and large language models can speed literature review, evidence extraction, clinician summaries, and trial matching, and the FDA's 2026 guidance clarifies which clinician-facing functions may fall outside device regulation. Trial matching links patients to biomarker-driven studies and generates real-world data of value to drug developers, while genomic risk tools for hereditary cancer and familial hypercholesterolemia and rapid genome sequencing for critically ill infants extend demand beyond oncology. Key trends include the move from static reports to decision support inside EHRs and prescribing systems, the combination of testing, data, and CDS in single platforms, and the reuse of genomic results across a patient's lifetime.
Segment Analysis
The report analyzes the market by component, application, integration type, deployment mode, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnerships, and investment.By component, the genomic clinical decision support market is segmented into software, knowledge bases & content, and services. Software, including standalone CDS platforms and EHR-embedded genomic modules, is expected to hold the largest share in 2026, as laboratories, cancer centers, and health systems have adopted oncology decision support, pharmacogenomic CDS, and interpretation and reporting tools, and EHR vendors are building genomic modules into their systems. Services are set to grow at the highest CAGR, driven by the difficulty of linking genomic results with EHRs and laboratory systems, demand for expert curation and interpretation, and the need to design, roll out, and tune genomic alerts and workflows. Knowledge bases and content are also expected to grow strongly as biomarkers, therapies, and guidelines multiply.
By application, the genomic clinical decision support market is segmented into oncology, pharmacogenomics, rare & inherited diseases, hereditary cancer & cardiovascular risk, reproductive & prenatal health, and other applications. Oncology, which covers therapy selection, clinical trial matching, and disease monitoring, is expected to lead in 2026, reflecting high volumes of comprehensive profiling and liquid biopsy tests, the growing number of biomarker-linked therapies and trials, and the difficulty oncologists face in reading complex reports. Pharmacogenomics is projected to record the highest CAGR, supported by the move toward preemptive testing, the delivery of results inside prescribing systems, evidence from the NHS PROGRESS trial that guidance changes prescribing for many patients, and well-established CPIC and DPWG guidelines. Hereditary risk tools are gaining use as testing reaches primary care and cardiology.
By integration type, the genomic clinical decision support market is segmented into EHR-integrated and standalone solutions, with standalone including web-based tools and laboratory portals. Standalone solutions are expected to account for the largest share in 2026, as web-based oncology platforms, laboratory reporting portals, and clinician applications from testing companies are widely used and need little EHR integration. EHR-integrated solutions are set to grow at the highest CAGR, driven by the uptake of EHR genomic modules, the need for drug-gene alerts at the moment of prescribing, wider exchange of structured results through HL7 FHIR Genomics, and clinicians' preference for guidance inside the systems they already use. This favors CDS providers with close EHR vendor ties.
By deployment mode, the genomic clinical decision support market is segmented into cloud-based and on-premise deployment. Cloud-based deployment is expected to hold the largest share in 2026 and to grow at the higher CAGR, as oncology tools and knowledge bases are delivered as cloud services that can be updated continuously, more health systems run cloud-hosted EHRs, and cloud solutions cost less to implement for smaller health systems and practices.
By end user, the genomic clinical decision support market is segmented into hospitals & health systems, clinical & reference laboratories, ambulatory & primary care practices, specialty clinics & cancer centers, and other end users such as pharmacies and payers. Hospitals & health systems are expected to account for the largest share in 2026, since genomic testing, cancer care, and EHR spending are concentrated in hospitals and integrated systems, they run genomic modules and pharmacogenomic programs, and they need enterprise-wide decision support. Ambulatory & primary care practices are expected to grow at the highest CAGR, supported by pharmacogenomic testing in general practice, as shown by the NHS PROGRESS trial, wider use of hereditary risk information in primary care, and adoption of cloud-based CDS by outpatient practices.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 19 countries and four rest-of-region groups. The regional analysis looks at genomic testing volumes, EHR adoption and genomic module use, pharmacogenomic programs, national genomic medicine initiatives, regulation, and the presence of CDS and testing companies.North America is expected to be the largest regional genomic clinical decision support market in 2026, supported by high oncology testing volumes, health system adoption of EHRs with genomic modules, pharmacogenomic programs at academic medical centers and integrated systems, and the U.S. base of Epic Systems, Oracle Health, Illumina, Tempus AI, and Velsera. Europe holds a significant share, backed by the NHS Genomic Medicine Service in England, the NHS PROGRESS trial, the inclusion of pharmacogenetic guidelines in the national medicines database of the Netherlands, and the presence of QIAGEN, Roche, and SOPHiA GENETICS, while software providing diagnostic or therapeutic information may fall under the EU IVDR or MDR.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, as oncology genomic testing grows in China, Japan, South Korea, and Australia, Japan covers cancer genomic medicine under its national health insurance system, Singapore runs population genomics programs, hospitals adopt EHRs, and interest in pharmacogenomics rises because several drug-response variants are more common in Asian populations. In the Middle East & Africa, Gulf genome projects in Saudi Arabia, the UAE, and Qatar support demand, while oncology genomic testing in Brazil and Mexico drives growth in Latin America.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis, together with company profiles that include business overviews, financials, genomic CDS and product/service portfolios, strategic developments, and SWOT analyses.The genomic clinical decision support market is moderately fragmented, with EHR vendors, CDS and interpretation software firms, testing companies, and content providers active across applications and regions. Vendors compete on the depth and currency of curated knowledge, EHR and laboratory system integration, trial matching, regulatory compliance, ease of use, and evidence of clinical utility. Leading players are embedding genomic results in EHR workflows, expanding curated content, applying AI to curation and interpretation, building trial matching tools, and combining testing, decision support, and data services. Recent developments include the FDA's January 2026 CDS software guidance, strong 2026 growth in Tempus AI's testing and data businesses, and Tempus AI's pending acquisition of Personalis.
Key companies profiled in the report include Epic Systems Corporation (U.S.), Oracle Corporation (Oracle Health) (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Illumina, Inc. (U.S.), Tempus AI, Inc. (U.S.), SOPHiA GENETICS SA (Switzerland), and Velsera, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global genomic clinical decision support market.
- Explains how oncology profiling, pharmacogenomic prescribing, and EHR genomic modules are driving demand for decision support.
- Assesses the impact of reimbursement limits, alert fatigue, knowledge maintenance, and interoperability gaps on adoption.
- Identifies high-growth opportunities across component, application, integration type, deployment mode, end user, and region.
- Tracks preemptive pharmacogenomics, AI-assisted curation, trial matching, and HL7 FHIR Genomics integration.
- Benchmarks EHR vendors, CDS software providers, and testing companies by content, integration, and regulatory position.
- Supports planning, partnering, and market entry decisions for vendors, laboratories, and health systems.
Key Questions Answered
- How big is the global genomic clinical decision support market today, and how will it grow through 2036?
- How are oncology profiling and biomarker-driven therapies increasing the need for decision support?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- What does the NHS PROGRESS trial show about pharmacogenomic guidance at the point of prescribing?
- How does the FDA's 2026 CDS software guidance affect genomic decision support products?
- Which component, application, integration type, deployment mode, and end user segments will grow the fastest?
- How quickly will EHR-integrated solutions replace standalone tools?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and how do they compete?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Genomic Clinical Decision Support Market, by Component
6. Genomic Clinical Decision Support Market, by Application
7. Genomic Clinical Decision Support Market, by Integration Type
8. Genomic Clinical Decision Support Market, by Deployment Mode
9. Genomic Clinical Decision Support Market, by End User
10. Genomic Clinical Decision Support Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Epic Systems Corporation
- Oracle Corporation
- F. Hoffmann-La Roche Ltd
- QIAGEN N.V.
- Illumina, Inc.
- Tempus AI, Inc.
- SOPHiA GENETICS SA
- Velsera, Inc.
